ATC Group: B02BD02 Coagulation factor VIII

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Blood and blood forming organs
2
Antihemorrhagics
3
Vitamin K and other hemostatics
4
Blood coagulation factors
5
B02BD02
Coagulation factor VIII

Active ingredients

Active Ingredient
Description

Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Lonoctocog alfa is a recombinant human protein that replaces the missing coagulation factor VIII needed for effective hemostasis. Lonoctocog alfa is a single polypeptide chain with a truncated B-domain that allows for a covalent bridge to link the factor VIII heavy and light chains. Lonoctocog alfa has demonstrated a higher VWF affinity relative to full-length rFVIII. VWF stabilizes factor VIII and protects it from degradation. Activated lonoctocog alfa has an amino acid sequence identical to endogenous FVIIIa.

Moroctocog alfa is a B-domain deleted recombinant coagulation factor VIII. Moroctocog alfa has functional characteristics comparable to those of endogenous factor VIII. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy, the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Octocog alfa (Full length recombinant human coagulation factor VIII (rDNA)) is a purified protein that has 2,332 amino acids. It is produced by recombinant DNA technology in baby hamster kidney cells (BHK) into which the human factor VIII gene has been introduced.

Medicines in this ATC group

Drug
Countries

Netherlands

Austria Brazil Canada Cyprus Finland ...

Brazil Canada New Zealand

Austria Cyprus Finland France Ireland ...

Austria Brazil Cyprus Finland France ...

South Africa

Austria Hong Kong Lithuania Poland Singapore ...

Brazil New Zealand Singapore

Austria Cyprus Finland France Ireland ...

Brazil Canada Hong Kong New Zealand

Poland Tunisia

Austria Finland Ireland Lithuania Netherlands ...

France Tunisia

Brazil Ireland Poland Singapore Spain ...

Austria Hong Kong Lithuania Poland Singapore ...

South Africa

Lithuania Poland South Africa

Hong Kong South Africa

Lithuania Poland

Austria Brazil Canada Cyprus Finland ...

Brazil Hong Kong Singapore South Africa

Austria Cyprus Ireland Lithuania Netherlands ...

Austria Brazil Canada Cyprus Finland ...

South Africa

Austria Cyprus Finland France Ireland ...

Austria Brazil Canada Cyprus Finland ...

Austria Canada Finland France Ireland ...

Austria France Ireland Lithuania Netherlands ...

Cyprus Lithuania Poland Singapore United Kingdom ...

Lithuania Poland

Austria Cyprus Finland France Ireland ...

Austria Ireland Lithuania Poland

Brazil Canada Hong Kong New Zealand Singapore ...

Brazil Canada

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)
Structured Product Monograph (SPM)
CA
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)
Structured Product Monograph (SPM)
CA